Alzheimer's Research UK has announced an £30m Drug Discovery Alliance, which will include a new institute on the Cambridge Biomedical Campus with CIMR Deputy Director David Rubinsztein as its academic lead. Its primary focus will be on the development of new treatments for Alzheimer's and other causes of dementia.
Andres Floto discusses in Cambridge News how altering the innate immune system response during infection may help provide improved treatments for conditions such as tuberculosis and cystic fibrosis.
In an interview with Cambridge News, David Rubinsztein outlines research efforts to target the autophagy process as a means of delaying the onset of neurodegenerative disease.
David Ron reviews his career choices in the autumn issue of EMBOencounters, as well as his election to the Royal Society and the importance of sustaining public support for science.
Wellcome-Beit Prize Fellowship
Congratulations to Eoin McKinney in the Smith lab, who has been awarded a Wellcome Trust Intermediate Clinical Fellowship and a Wellcome-Beit Prize Fellowship, the latter of which recognizes just four outstanding biomedical researchers each year.